Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio— have products in the pipeline that could ...
The disorder that Irfan had tested positive for was Mucopolysaccharidosis Type II (MPS II), also known as Hunter Syndrome, ...
You will not be able to apply after this date has passed. Become part of a stimulating and supportive research community at one of the top 5 Geography departments in the UK (THE World University ...
Objectives Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with ...
A larger-than-normal head is one of the physical characteristics of Hunter syndrome, according to the advocacy group Project Alive. “The prognosis was that he might not make it to his teenage ...
Nippon Shinyaku has paid $110 million upfront for the rights to sell two of Regenxbio’s gene therapies for mucopolysaccharidosis in the US and Asia. … ...
RegenxBio said Tuesday that Kyoto, Japan’s Nippon Shinyaku Co. Ltd. will develop and commercialize its one-time gene therapies for Hunter syndrome ... within that geography, the local company ...
This leads to buildup in the organs and can cause damage over time that affects patients’ physical and mental abilities. RegenXBio gets FDA support for Hunter syndrome gene therapy's accelerated ...
The partnership will focus on advancing RGX-121 as a treatment for mucopolysaccharidosis II (MPS II), also known as Hunter syndrome, and RGX-111 for treating mucopolysaccharidosis I (MPS I), also ...
One of the treatments, for a progressive disorder known as Hunter syndrome, could secure approval in the U.S. as soon as late this year. Should that happen, Regenxbio will retain rights to any ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback